2-(4-fluorophenyl)-7,8-dihydroquinolin-5(6H)-one | 72839-21-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-(4-fluorophenyl)-7,8-dihydroquinolin-5(6H)-one
• 英文别名: 2-(4-fluorophenyl)-7,8-dihydro-6H-quinolin-5-one
• CAS: 72839-21-5
• 化学式: C₁₅H₁₂FNO
• 分子量: 241.265
• InChiKey: ZMJNFYIESJXWHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-fluorophenyl)-7,8-dihydroquinolin-5(6H)-one 、 氨基硫脲 在 硫酸 作用下， 以 甲醇 为溶剂， 以80%的产率得到(E)-2-(2-(4-fluorophenyl)-7,8-dihydroquinolin-5(6H)-ylidene)hydrazinecarbothio amide
  参考文献：
  名称：

  Synthesis, in vitro, and in vivo (Zebra fish) antitubercular activity of 7,8-dihydroquinolin-5(6H)-ylidenehydrazinecarbothioamides

  摘要：

  We, herein, describe the synthesis of a series of novel aryl tethered 7,8-dihydroquinolin-5(6H)-ylidenehydrazinecarbothioamides 4a-v, which showed in vitro and in vivo antimycobacterial activity against Mycobacterium tuberculosis (Mtb) H37Rv. The intermediates dihydro-6H-quinolin-5-ones 3a-v were synthesized from beta-enaminones, reacting with cyclochexane-1,3-dione/5,5-dimethylcyclohexane-1,3-dione and ammonium acetate using a modified Bohlmann-Rahtz reaction conditions. They were further reacted with thiosemicarbazide to give the respective hydrazine carbothioamides 4a-v. All the new analogues 4a-v, were characterized by their NMR and mass spectral data analysis. Among the twenty-two compounds screened for in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC27294), two compounds, 4e and 4j, exhibited the highest inhibition with an MIC of 0.39 mu g/mL. Compounds 4a, 4g, and 4k were found to inhibit Mtb at an MIC of 0.78 mu g/mL. Hydrazinecarbothioamides 4a-k, exhibited enhanced activity than dihydroquinolinones 3a-k. The observed increase in potency provides a clear evidence that hydrazinecarbothioamide is a potential pharmacophore, collectively imparting synergistic effect in enhancing antitubercular activity of the dihydroquinolinone core. The in vivo (Zebra fish) antimycobacterial screening of the in vitro active molecules led to the identification of a hit compound, 4j, with significant activity in the Mtb nutrient starvation model (2.2-fold reduction). Docking studies of 4j showed a hydrogen bond with the P156 residue of the protein.

  DOI：

  10.1016/j.bioorg.2020.103626
• 作为产物：
  描述：

  4-氟苯乙酮 在 cerium(III) chloride heptahydrate 、 ammonium acetate 、 sodium iodide 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 、 异丙醇 为溶剂， 反应 11.0h， 生成 2-(4-fluorophenyl)-7,8-dihydroquinolin-5(6H)-one
  参考文献：
  名称：

  Synthesis, in vitro, and in vivo (Zebra fish) antitubercular activity of 7,8-dihydroquinolin-5(6H)-ylidenehydrazinecarbothioamides

  摘要：

  We, herein, describe the synthesis of a series of novel aryl tethered 7,8-dihydroquinolin-5(6H)-ylidenehydrazinecarbothioamides 4a-v, which showed in vitro and in vivo antimycobacterial activity against Mycobacterium tuberculosis (Mtb) H37Rv. The intermediates dihydro-6H-quinolin-5-ones 3a-v were synthesized from beta-enaminones, reacting with cyclochexane-1,3-dione/5,5-dimethylcyclohexane-1,3-dione and ammonium acetate using a modified Bohlmann-Rahtz reaction conditions. They were further reacted with thiosemicarbazide to give the respective hydrazine carbothioamides 4a-v. All the new analogues 4a-v, were characterized by their NMR and mass spectral data analysis. Among the twenty-two compounds screened for in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC27294), two compounds, 4e and 4j, exhibited the highest inhibition with an MIC of 0.39 mu g/mL. Compounds 4a, 4g, and 4k were found to inhibit Mtb at an MIC of 0.78 mu g/mL. Hydrazinecarbothioamides 4a-k, exhibited enhanced activity than dihydroquinolinones 3a-k. The observed increase in potency provides a clear evidence that hydrazinecarbothioamide is a potential pharmacophore, collectively imparting synergistic effect in enhancing antitubercular activity of the dihydroquinolinone core. The in vivo (Zebra fish) antimycobacterial screening of the in vitro active molecules led to the identification of a hit compound, 4j, with significant activity in the Mtb nutrient starvation model (2.2-fold reduction). Docking studies of 4j showed a hydrogen bond with the P156 residue of the protein.

  DOI：

  10.1016/j.bioorg.2020.103626

文献信息

• Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
  申请人：Jirgensons Aigars

  公开号：US20050197361A1

  公开（公告）日：2005-09-08

  The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutially acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

  该发明涉及四氢喹诺酮衍生物及其药用可接受的盐。该发明还涉及一种制备这种化合物的方法。该发明的化合物是I组mGluR拮抗剂，因此对于控制和预防急性和/或慢性神经系统疾病非常有用。
• Chemoselective Condensation of 3-Amino-2-cyclohexenones with Cinnamaldehydes: Switchable Synthesis of Dihydroquinolinones and Hexahydroacridinediones
  作者：Ling Jiang、Kun He、Weikun Zeng、Zhi Qiao、Xizhong Song、Kaixiu Luo、Jingbo Chen、Jun Lin、Yi Jin

  DOI：10.1021/acs.joc.3c00011

  日期：2023.5.5

  cinnamaldehydes for switchable synthesis of dihydroquinolinones and hexahydroacridinediones was developed. Mechanism analysis showed that the formation of dihydroquinolinones involved trimolecular condensation and oxidative aromatization, while the formation of hexahydroacridinediones involved acid hydrolysis of enaminone and dehydration-aromatization. This strategy provides a convenient way to switch from the

  在此，开发了 3-氨基-2-环己烯酮和肉桂醛的化学选择性缩合，用于二氢喹啉酮和六氢吖啶二酮的可切换合成。机理分析表明，二氢喹啉酮的形成涉及三分子缩合和氧化芳构化，而六氢吖啶二酮的形成涉及烯胺酮的酸水解和脱水-芳构化。该策略提供了一种从相同底物转换为生产两种不同喹啉酮衍生物的便捷方法。
• SCHROEDER E.; LEHMANN M.; BOETTCHER I., EUR. J. MED. CHEM.-CHIM. THER., 1979, 14, NO 4, 309-315
  作者：SCHROEDER E.、 LEHMANN M.、 BOETTCHER I.

  DOI：——

  日期：——
• TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP1723116A2

  公开（公告）日：2006-11-22
• US7598384B2
  申请人：——

  公开号：US7598384B2

  公开（公告）日：2009-10-06